career highlights

career highlights

Patrick Terry can be considered the godfather of personalized medicine in the age of genetics.

Dr. Raju Kucherlapati

Professor, Medicine, Harvard Medical School
Scientific Director, Harvard-Partners Center for Genetics and Genomics.
Personalized Medicine Coalition/Harvard Symposium, 2014

somalogic, inc., boulder co

(Exit: SPAC Merger 2021)

chief commercial officer

Recruited to advance the new commercial initiatives of this twenty-year-old private proteomics R&D company.
  • Crafted and operationalized multi-channel clinical strategy for their R&D proteomics asset.
  • Built and mentored a 20-member team into a highly adaptive, cohesive, and innovative commercial group.
  • Played an integral strategic role in operationalizing $150M pharmaceutical partnership investments.
  • Secured a novel strategic partnership with a Japanese conglomerate for international market creation.

2019 - 2021

MEMED DIAGNOSTICS., Haifa, Israel

(Exit: IPO 20XX)

Co-Founder, Board Member, & Chief Commercial Officer

Established a personalized medicine infectious disease biotechnology startup company based on technology created in Israel that creates rapidly developing and commercializing revolutionary solutions to infectious diseases with antibiotic resistance. Secured tens of millions of investment capital and DoD funds for the startup. Guide, mentor, and support a growing international management team. Continue to serve as a Board Member and Business Advisor.
  • Co-designed an innovative blood test that allows for rapid diagnosis of infection, thereby targeting antibiotics.
  • Achieved recognition by the World Health Organization for pioneering solutions that will impact million lives.
  • Scaled the organization from a 4-person startup to a successful private company now valued at over $1.5B.

2012 - 2021

INIVATA UK LTD., Cambridge, UK / Raleigh, NC

(Exit: Acquired)

Co-Founder, Independent Board Director, Chief Commercial Officer

Co-founded a new personalized medicine biotechnology startup out of Cambridge University and secured the needed risk capital funding and international investor buy-in to enable the company’s successful launch InVisionFirst®

  • Co-designed an innovative blood test that allows for rapid diagnosis of infection, thereby targeting antibiotics.
  • Achieved recognition by the World Health Organization for pioneering solutions that will impact million lives.
  • Scaled the organization from a 4-person startup to a successful private company now valued at over $1.5B.

2015 - 2019

TECHNIC SOLUTIONS, Bethesda, MD / Cambridge, MA

(Exit: Acquired)

Founder, CEO, & Personalized Medicine Division Head

Consultant to 85+ multi-national life science client organizations in the area of applied science commercialization. 

  • Facilitated transitional activities following the acquisition of consulting company by Scientia Advisors.
  • Created a recognized center-of-excellence for management consulting in the business community.
  • Managed many multinational commercialization projects in Rx/Dx/MedTech/Digital Health.
  • Managed a diverse and growing client base that enable Scientia Advisors to be acquired.

2008 - 2012

GENOMIC HEALTH, Palo Alto, CA / Geneva, Switzerland

(Exit: Acquired)

Founder, CEO, & Personalized Medicine Division Head

Created a new biotechnology company to drive precision medicine in better supporting patients living with cancer. Secured $154M in venture capital during a Silicon Valley recession. Leveraged a data-driven and personalized approach to medicine to develop continuously disruptive solutions in the management of clinical oncology.

  • Successfully organized 800+ stakeholder groups across the United States into one diverse community focused on transforming personalized medicine approaches and patient experiences.
  • Enabled advances in innovation that previously averaged 20 years to clinical adoption in just over five years.
  • Educated and trained the cancer community in adopting a new treatment paradigm (OncoType DX®) that has saved millions of individuals from experiencing ineffective cytotoxic cancer treatments.
  • Recognized for developing a new commercial paradigm for enabling the delivery of personalized medicine.

1999 - 2008